Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Select Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 410 (final count)
- Started
- Feb 25, 2020
- Main results expected
- Oct 2026
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Incidence of dose-limiting toxicity (DLT)s
Measured over: Up to ~28 days after each dose
Phase 1: Incidence of adverse events (AE) and serious adverse events (SAE)
Measured over: Up to 30 days after the last dose of study therapy
Phase 1: Number of participants with dose interruptions, dose reductions, or dose discontinuations
Measured over: Up to ~12 months
Phase 1: Number of participants with abnormal laboratory test results (hematology)
Measured over: Up to 30 days after the last dose of study therapy
Phase 1: Number of participants with abnormal laboratory test results (chemistry)
Measured over: Up to 30 days after the last dose of study therapy
Phase 1: Number of participants with abnormal laboratory test results (coagulation)
Measured over: Up to 30 days after the last dose of study therapy
Phase 1: Number of participants with abnormal urinalysis
Measured over: Up to 30 days after the last dose of study therapy
Phase 1: Number of participants with abnormal vital signs
Measured over: Up to 30 days after the last dose of study therapy
Phase 1: Mean change from baseline in QTcF interval
Measured over: Up to 30 days after the last dose of study therapy
Phase 2: Best overall response (BOR)
Measured over: Up to ~2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04262466 · record last updated 2026-03-06 · checked 2026-11-09 15:47 UTC